The effect of thymalin, dalargin and "Mucosalin" on the course of an experimental duodenal ulcer
Lukash NV, Polishchuk TF · 1995 · Lik Sprava. 1995;(1-2):53-55. PMID 7483545
This source appears in the Thymalin–Dalargin evidence review. A single-agent experiment, comparative study or patent alternative is not automatically a combined-treatment trial.
Reported findings and study design
Narrative findings; numerical extraction incomplete
The authors described protection in the order Mucosalin > Dalargin > Thymalin. The abstract gives no numerical lesion scores or combined-treatment result.
80 male Wistar rats across an experimental duodenal-ulcer comparison; per-arm numbers unavailable.
Protocol information
Dose, route and treatment schedule are not sufficiently described in the checked abstract.
Protocol source ↗ · Original indexed abstract; protocol unavailable
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Relative protective activity | Mucosalin > Dalargin > Thymalin, as ranked in the abstract | Qualitative ranking; no effect size, uncertainty or pairwise significance provided |
| Animal program | 80 male Wistar rats in total | Not 80 rats per peptide and not a human cohort |
| Combination exposure | No simultaneous Thymalin plus Dalargin administration established by the abstract |
Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Source for the extracted data ↗ · Checked 2026-11-08
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Dose, route, duration, individual arm sizes and lesion-score tables are unavailable in the checked abstract.
- Mucosalin is a separate experimental extract; its result is not transferred to either Thymalin or Dalargin.
- Comparative animal protection is not evidence of synergy or human ulcer healing.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original indexed abstract
Review depth: Indexed abstract and citation checked; full original outcome tables not recovered
Source access and review scope
Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Recorded source-check date: 2026-11-08. This date does not imply a completed systematic review.
Source type: Original journal publication
Citation and original source
Original source: Lukash NV, Polishchuk TF. The effect of thymalin, dalargin and "Mucosalin" on the course of an experimental duodenal ulcer Lik Sprava. 1995;(1-2):53-55. PMID 7483545 1995.
Molekul research summary: https://molekul.io/research/thymalin-dalargin-ulcer-rats-1995. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Thymalin
Thymus-derived peptide mixture with historical Russian studies in autoimmune cytopenias and thyroiditis, alongside other treatments. It is distinct from synthetic Thymogen and Thymodepressin.
Dalargin
A Soviet synthetic opioid hexapeptide investigated in cytoprotection, stress, hypoxia, ischemia and trauma. Its enkephalin lineage is distinct from organ-derived peptide bioregulators; historical proposals and laboratory effects are not established clinical indications.